- ASBP shares are volatile intraday. As of ~14:40 UTC, the stock traded around $0.119, swinging between $0.1189–$0.2471 on ~140M shares. Pre‑market action briefly pushed the price higher before reversing. [1]
- No new company press releases or SEC filings were posted today (Nov. 11). The most recent company events remain last week’s CPHI Frankfurt partnering update (Nov. 6) and special‑meeting results (Nov. 5). [2]
- Nasdaq compliance remains the overhang. On Oct. 17, Aspire disclosed it requested a hearing after receiving an Oct. 15 delisting notice tied to both market‑value and bid‑price deficits; the hearing request stays suspension while a panel reviews the plan. [3]
What moved ASBP today (Nov. 11)
Trading in Aspire Biopharma swung sharply. A pre‑market “health‑care movers” screen showed ASBP briefly up more than 30%, before regular‑session selling pulled shares lower on very heavy volume. Mid‑session, ASBP was down roughly 20–25% versus Monday’s close, with an exceptionally wide intraday range—characteristic of micro‑cap names facing near‑term listing and financing milestones. [4]
While price action is noisy, there were no fresh corporate announcements today. The latest company communication remains last week’s trade‑show recap from CPHI Frankfurt, where Aspire says it held 16 formal meetings and multiple informal conversations with global pharmas regarding potential collaboration and licensing around its sublingual high‑dose aspirin program. [5]
The latest confirmed developments investors are watching
1) Special meeting results: reverse‑split authority and share‑issuance approval (Nov. 5)
In an 8‑K filed Nov. 5, Aspire reported that shareholders approved giving the board discretion to implement a reverse stock splitwithin a 1‑for‑5 to 1‑for‑40 range any time within one year. Investors also approved, for Nasdaq Rule 5635(d) purposes, potential issuance of more than 19.99% of outstanding shares related to previously issued convertible notes (with a specified floor price calculation). These actions are commonly used by small‑cap issuers to address bid‑price compliance and capital‑structure flexibility. [6]
2) Listing status: appeal underway after delisting notice (Oct. 15 letter; 8‑K filed Oct. 17)
Aspire disclosed that Nasdaq’s staff notified the company on Oct. 15 that its securities are subject to delisting for two independent deficiencies: falling below the $50M Market Value of Listed Securities threshold and the $1.00 minimum bid. Aspire requested a hearing and paid the associated fee, which stays suspension pending the panel’s decision and any extension the panel may grant (up to 180 days from the delist determination). [7]
3) Business development & clinical backdrop (latest: Nov. 6 press release)
At CPHI Frankfurt, Aspire highlighted warmer‑than‑usual inbound interest in partnerships for its patent‑pending sublingual platform, specifically the high‑dose aspirin intended for suspected myocardial infarction (heart attack). Management cited a series of face‑to‑face meetings with prospective partners and reiterated plans to accelerate partnering discussions following positive final and top‑line Phase 1 results reported earlier this year. [8]
- Final results (Sept. 3): Aspire reported its sublingual aspirin achieved higher and faster mean plasma ASA concentrations versus chewed tablets and produced rapid thromboxane B₂ inhibition within minutes—a pharmacodynamic signal aligned with faster antiplatelet onset. [9]
- Roadmap (Oct. 2): The company previously outlined a milestone plan centered on a 2025 FDA submission for the aspirin program and 2026 technical milestones for additional sublingual candidates (e.g., semaglutide, ED medication). [10]
What’s next
- Potential reverse split (timing at board’s discretion): With authority now granted, the board can effect a split at any ratio between 1‑for‑5 and 1‑for‑40 within the next 12 months—a lever commonly pulled to restore $1 bid‑price compliance. No effective date has been announced. [11]
- Nasdaq hearing outcome: The company will present its plan to cure both the market‑value and bid‑price deficiencies. A panel can grant up to 180 additional days; approval isn’t guaranteed. [12]
- Upcoming financial cadence: Third‑party data providers list conflicting near‑term earnings dates (one major exchange site lists an estimated Nov. 12; a separate data vendor lists Nov. 24). Aspire has not issued an official earnings release for today. Treat those dates as tentative until the company posts a definitive notice. [13]
- Partnering updates: Following last week’s CPHI outreach, watch for any term sheets or co‑development/licensing news tied to the aspirin program or the broader sublingual platform. [14]
Today’s market context for ASBP
Micro‑cap biotech stocks can move dramatically on order‑flow and headline expectations. In ASBP’s case, listing‑status uncertainty and the prospect of a reverse split are likely amplifying intraday swings. Liquidity is also thin relative to larger caps, which can magnify price impact from day traders and momentum algorithms. Today’s tape reflects that dynamic: a pre‑market pop faded into a midday sell‑off despite no new company disclosure. [15]
Company snapshot
Aspire Biopharma Holdings completed its business combination earlier this year and is developing a sublingual drug‑delivery platform intended to speed onset and improve bioavailability for certain approved drugs and supplements—initially high‑dose aspirin for emergency use in suspected heart attack. [16]
Bottom line for Nov. 11, 2025
There were no new press releases or SEC filings from Aspire today. The stock’s whipsaw reflects speculation around near‑term compliance actions (potential reverse split), the Nasdaq hearing, and ongoing partnering prospects following the CPHI meetings. For investors and observers, the next confirmed catalyst will likely be either a board action on the split, an update from the Nasdaq panel, or formal financial reporting guidance from the company. [17]
Sources
- SEC Form 8‑K (Nov. 5, 2025) — Special meeting results (reverse‑split authority; share‑issuance approval under Nasdaq Rule 5635(d)). [18]
- SEC Form 8‑K (Oct. 17, 2025) — Nasdaq delisting notice and hearing request; stay of suspension pending panel decision. [19]
- ACCESS Newswire (Nov. 6, 2025) (syndicated) — CPHI Frankfurt partnering update and background on aspirin program. [20]
- BioSpace (Oct. 2, 2025) — Milestone roadmap for aspirin filing and 2026 program targets. [21]
- Yahoo Finance (Sept. 3, 2025) — Final Phase 1 results highlighting rapid ASA exposure and TxB₂ inhibition. [22]
- Nasdaq earnings page (estimate only) and Benzinga pre‑market movers (today) for calendar and early price action context. [23]
- Real‑time price/volume via market data widget above.
Editor’s note: This article is for informational purposes and does not constitute investment advice. Always verify tentative dates with official company releases and SEC filings.
References
1. www.benzinga.com, 2. www.barchart.com, 3. www.sec.gov, 4. www.benzinga.com, 5. www.barchart.com, 6. www.sec.gov, 7. www.sec.gov, 8. www.barchart.com, 9. finance.yahoo.com, 10. www.biospace.com, 11. www.sec.gov, 12. www.sec.gov, 13. www.nasdaq.com, 14. www.barchart.com, 15. www.benzinga.com, 16. www.sec.gov, 17. www.sec.gov, 18. www.sec.gov, 19. www.sec.gov, 20. www.barchart.com, 21. www.biospace.com, 22. finance.yahoo.com, 23. www.nasdaq.com
